Akoya Biosciences has certified Precision for Medicine as part of its global network of Qualified CRO services providers. Precision for Medicine, as a recognized leader in the field of tissue and liquid biopsy analysis to support therapeutic development, has demonstrated excellence in using Akoya’s PhenoImager® HT (formerly known as the Vectra Polaris) quantitative imaging platform for multiplex immunofluorescence (mIF) assays. Precision has an established history of leadership with this platform; in 2018, Precision for Medicine partnered with Akoya in expanding the uses of the PhenoImager HT, including becoming the first company to use this platform to analyze circulating tumor cells in support of oncology therapeutic development. This recognition as a certified partner is a further demonstration of Precision’s focus on pushing forward the science of clinical development.
We are excited to be an Akoya certified partner, which exemplifies Precision’s commitment to leveraging state of the art technologies to help accelerate our customers’ clinical research programs as they strive to create transformational therapies for patients with cancer, autoimmune disorders, and other complex diseases.
Jesus Garcia, PhD, Senior Scientific Liaison at Precision for Medicine
Clinical Utility of Multiplex Immunofluorescence Tissue Profiling
Multiplex immunofluorescence is a technology that allows for simultaneous detection of multiple target proteins in the same tissue section with single-cell data resolution. Tissue multiplexing immunofluorescence capabilities allow for the detection of up to 9 colors, which can be used to phenotype and identify important cell populations, and also to provide information on the spatial distribution and activation state of different types of immune cell populations within a sample.
At Precision for Medicine, we have developed a digital pathology workflow for the PhenoImager HT incorporating automation at nearly every step – which is essential in limiting errors and variability, maximizing throughput, and reducing time to result. (Figure 1).
This workflow generates complex spatial information of a tumor or tissue sample, visualizes the spatial distribution of proteins within a single cell, and provides information on pharmacodynamics, mechanism-of-action, and progression or state of disease. Importantly, Precision offers quantitative and high throughput mIF on fresh and archival tissues and cells isolated from liquid biopsies (e.g., circulating tumor cells).
In a recent study, we demonstrated the ability of our molecular profiling tools to detect patients who might exhibit improved therapeutic response based on analysis of tumor infiltration by CD4+ and CD8+ cells. Once the tissue was classified, an infiltration analysis tool was used to define regions of quantification of immune cell infiltration. These deep insights into the level of immune cell infiltration allowed for distinction between hot and cold tumors, data which can be used for exploratory endpoints and screening, with potential use in clinical trials to determine eligibility and to stratify patients who are most likely to respond to immunotherapy.
Example: Immune cell infiltration analysis and histogram
Being an Akoya certified partner is another example of how Precision for Medicine is bringing new technologies, expertise, and operational excellence to improve the speed, cost, and success rate of transformational therapies for patients. Learn more about our other tissue and liquid biopsy analysis services.
Jesus Garcia, PhD, is a tissue and liquid biopsy expert with extensive experience in a wide range of histopathology assays and digital pathology solutions. Part of the
implementation of new technologies at MD Anderson Cancer Center in collaboration with immuno-oncology leaders. Currently focused on partnering with biopharma to develop tissue and liquid biopsy biomarker strategies for clinical trials, and to implement digital pathology and AI in the drug development process.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.